Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

Stay Away From Blue Apron Stock for Now

Blue Apron stock has lost more than 95% of its value over the past two and a half years, and this decline won't end anytime soon.

5G Letdown Could Delay Turnaround For Nokia Stock

Nokia had a bright future in 5G, but investors have been disappointed by fierce competition and a delayed turnaround.

The Infused Beverage Miss Is Symptomatic of the Trouble With CGC Stock

CGC stock announced its delayed the launch of its cannabis-infused beverage line. Here is what this means for the company going forward.

Slowdown Fears Could Be the Last Straw for NIO Stock

Cash burn continues and further equity dilution will take Nio stock lower. Margin pressure to sustain due to competition.

Pier 1 Is the Next Retailer Heading Into Bankruptcy

PIR stock is dead in the water. Although its cost-cutting initiatives may keep it afloat for some time, the underlying retailer can’t avoid the inevitable.

BABA Stock Weakened Before the Coronavirus and Looks Worse Now

After a strong rally, Alibaba stock has hit a wall. And yes, this is mostly due to the coronavirus. However, the worst may not be over.

Sell Canopy Growth Shares Now Before CGC Loses Its Spark

Investors may not offer CGC stock a Constellation premium much longer, which means shares could head much lower.

Beyond Meat Stock Just Got Hit With the Ugly Stick

Although the meatless meat trials at major fast food chains make room for opportunity, many other problems loom over Beyond Meat stock.

Is PIR Stock the Canary in a Coal Mine?

Although PIR stock is tumbling to the point of non-existence, investors shouldn’t dismiss this as poor management. Rather, Pier 1’s troubles could be a harbinger for more serious concerns.

Sell Apple Stock Before the Bubble Bursts

With iPhone sales still stagnant and services revenue not quite ready for heavy lifting, Apple stock seems like a dangerous bet today.

3 Reasons Why FuelCell Stock Is a Strong Sell

FuelCell Energy stock enjoyed an incredible run over the past three months. But the last quarterly earnings results showed that the good times have ended.

3 Airline Stocks to Sell This Week in Wake of the Coronavirus

With the coronavirus on consumers' minds, along with continued issues with the 737 Max grounding, these three airline stocks could go lower.

Nokia Stock Eventually May Move Higher, but There Are Better Bets

Margin will remain under pressure through 2020. Long-term growth to be driven by 5G, internet of things and licensing cash flows.

Pricey Shopify Stock Represents What’s Wrong With the Stock Market

Now does not look like the time to buy Shopify stock, as valuations outpace fundamentals in this wacky market environment.

Chesapeake Energy Stock Needs a Miracle to Avoid $0

CHK stock is testing the lows again as natural gas futures collapse. There's hope for a revival -- but it will take a historic energy rally.

Naked Brands Is Not an Emperor, And It Probably Doesn’t Have Any Clothes

When a stock sheds more than 98% of its value in a year, there are plenty of dark times to point to, but in the case of Naked, the retrenchment is all the more alarming when considering the stock is off 49.59% over the past month. It was about a month that the company engineered a 1-for-100 reverse split designed to inflate its share price. Today, it looks like all that reverse split was good for was giving bears a higher price to short from.

Avoid Richly Valued Slack Stock Until It Drops Below $20

Although Slack stock is down 50% from its opening price, shares still aren't cheap enough to warrant buying the dip.

4 Large-Cap Stocks Getting Crushed by Coronavirus

As a result of the new virus, many well-known and widely-held large-cap stocks are beginning to roll over.

The Future Doesn’t Look Too Bright For Acasti Pharma Stock

Following unsuccessful Phase 3 clinical trial results for its core CaPre treatment, Acasti and ACST stock look doomed.